Novo Stock Faces Pressure as GLP-1 Drugs See Rising Competition from Eli Lilly
KEY POINTS COPENHAGEN — Novo Nordisk is navigating a rapidly evolving pharmaceutical landscape as competition intensifies in the GLP-1 weight loss drug market. The Danish drugmaker, an early pioneer with its diabetes medication Ozempic, which also supports weight management, is facing pressure from Eli Lilly’s newly launched GLP-1 therapies, Mounjaro for diabetes and Zepbound for … Read more